KIT-exon-11 mutations in GISTs correlate with higher partial response rates and improved surgical outcomes with neoadjuvant Gleevec. Non-KIT exon 11 mutations and wild-type KIT/PDGFRA GISTs show less ...
WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II ...
As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback